Senvest Management LLC boosted its holdings in shares of Trinity Biotech plc (NASDAQ:TRIB) by 25.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 892,488 shares of the company’s stock after buying an additional 178,666 shares during the quarter. Senvest Management LLC owned about 3.71% of Trinity Biotech worth $5,007,000 at the end of the most recent quarter.
A number of other institutional investors have also bought and sold shares of the business. State Street Corp increased its position in Trinity Biotech by 2.1% during the second quarter. State Street Corp now owns 37,614 shares of the company’s stock worth $225,000 after buying an additional 781 shares during the last quarter. Teton Advisors Inc. boosted its holdings in Trinity Biotech by 0.3% during the second quarter. Teton Advisors Inc. now owns 231,730 shares of the company’s stock valued at $1,390,000 after acquiring an additional 800 shares during the period. Lapides Asset Management LLC boosted its holdings in Trinity Biotech by 0.4% during the second quarter. Lapides Asset Management LLC now owns 1,289,600 shares of the company’s stock valued at $7,738,000 after acquiring an additional 5,500 shares during the period. Paradice Investment Management LLC boosted its holdings in Trinity Biotech by 0.8% during the second quarter. Paradice Investment Management LLC now owns 1,639,296 shares of the company’s stock valued at $9,836,000 after acquiring an additional 12,800 shares during the period. Finally, Adirondack Research & Management Inc. boosted its holdings in Trinity Biotech by 4.1% during the third quarter. Adirondack Research & Management Inc. now owns 334,175 shares of the company’s stock valued at $1,875,000 after acquiring an additional 13,191 shares during the period. 60.47% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Trinity Biotech plc (NASDAQ TRIB) opened at $5.64 on Wednesday. The company has a current ratio of 5.16, a quick ratio of 3.77 and a debt-to-equity ratio of 0.90. Trinity Biotech plc has a fifty-two week low of $4.22 and a fifty-two week high of $7.27. The stock has a market cap of $131.99, a PE ratio of 91.50 and a beta of 1.41.
Separately, Zacks Investment Research cut shares of Trinity Biotech from a “hold” rating to a “strong sell” rating in a report on Wednesday, November 1st.
ILLEGAL ACTIVITY NOTICE: “Senvest Management LLC Acquires 178,666 Shares of Trinity Biotech plc (TRIB)” was first published by Week Herald and is owned by of Week Herald. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international trademark & copyright laws. The legal version of this report can be read at https://weekherald.com/2017/12/13/senvest-management-llc-raises-holdings-in-trinity-biotech-plc-trib.html.
Trinity Biotech Company Profile
Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company’s products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine.
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.